News

As per the terms of the agreement, Eisai is expected to get exclusive worldwide rights (excluding some countries) for the development and commercialization o f compound as well

The study is expected to show a clinically meaningful and significant reduction in overall mortality between the vaccine and control group and envisages enrolling about 800 subjects. The

As per the agreement, Invida will leverage its capabilities for the management of all of the marketing and sales activities for Roche‘s primary care products, including Xenical, and

The increase of approximately $796,000 in revenues from the fourth quarter of 2009 compared to the fourth quarter of 2010 was primarily due to increased licensing fees due

The company has received the US Food and Drug Administration approval for Axiron on 23 November 2010. Eli Lilly said the study results demonstrated that Axiron helped in

PGXL Laboratories provides pharmacogenetic testing and interpretive services. It has developed CYP2C9/VKORC1 tests for accurate anticoagulant dosing. Along with its clinical practice, PGXL performs contract research for manufacturers

The Phase 3 trials include two studies in treatment-naive and one study in treatment-experienced chronic genotype-1 HCV patients. Boehringer Ingelheim expects to conduct the two Phase 3 studies

The biodegradable nanoparticles could be topically applied to the skin or injected into the body to treat MRSA skin infections. IBM Research – Almaden Advanced Organic Materials scientist

REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active control agent. The study results showed that